# OnCo record paper-joseph-perioperative-nsclc-cost-effectiveness-sri-lanka-bmjonc-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-joseph-perioperative-nsclc-cost-effectiveness-sri-lanka-bmjonc-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-joseph-perioperative-nsclc-cost-effectiveness-sri-lanka-bmjonc-2026" ;
  schema:name "Cost-effectiveness of perioperative novel therapies for stage II to III non-small cell lung cancer in Sri Lanka"@en ;
  schema:description "At a threshold of US$6,700 per quality-adjusted life year, adjuvant osimertinib, adjuvant alectinib and neoadjuvant nivolumab were cost-effective in Sri Lanka; at US$3,000 only the osimertinib strategies remained so."@en ;
  schema:url <https://onco.cc/key-papers/paper-joseph-perioperative-nsclc-cost-effectiveness-sri-lanka-bmjonc-2026/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  schema:citation <https://doi.org/10.1136/bmjonc-2025-001046>, <https://pubmed.ncbi.nlm.nih.gov/42369562/> ;
  schema:sameAs <https://doi.org/10.1136/bmjonc-2025-001046> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Joseph N, Kularatna S, Senanayake S." ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:institutions <https://onco.cc/institutions/sri-lanka-ministry-of-health/> .
